Inconsistent chatter from a Sacramento-based 'Sconi attorney.

Monday, August 01, 2005

Is Giambi back on the "sauce"?

I was wondering whether Giambi was back on steroids or its untestable equivalent (TGH or HGH) when I saw that it looked like he had gained some weight from this off-season until now. Then I saw these numbers (at-bats, home runs, runs batted in, walks, strike-outs, batting average, slugging percentage):

2004 - 264 AB, 12 HR, 40 RBI, 47 BB, 62 K, .208 AVG, .379 SLG
April-May 2005 - 121 AB, 4 HR, 13 RBI, 28 BB, 39 K, .231, .344 SLG
June-July 2005 - 134 AB, 15 HR, 33 RBI, 45 BB, 32 K, .336 AVG, .703 SLG

Is it possible that Giambi took something mid-season in order to get out of the season and one-half slump he was mired in? I mean, Giambi went from being on the cusp of being cut, to being the biggest hitter on the Evil Empire in like a month? How can this be? [insert the picture of Jose Canseco injecting Jason Giambi in the butt, here]. Just look at his Batting Average and Slugging % increase, as well as this difference between Strikeouts and Walks. All of these things point to better eyesight, hand-eye coordination, and increased strength.

Well, rumor has it that Palmeiro took the 'roid that he got cuaght for sometime near the end of April early May. We know Palmeiro and Giambi were both clean during spring training, because they passed their respective tests at that time. But what were Palmeiro's stats pre and post incident you might ask?

April 2005 - 77 AB, 1 HR, 7 RBI, 6 BB, 9 K, .247 AVG, .325 SLG
May-July 2005 - 266 AB, 17 HR, 42 RBI, 37 BB, 29 K, .289 AVG, .488 SLG

His increase was not nearly as sharp as Giambi. However, there is still a noticeable climb in Batting Average, Slugging %, as well as Walks and Strikeouts.

All I am saying, is don't be surprised if Giambi is the next big name to get hooked by the MLB in its 'roid ruse. And even if he gets by unscathed, don't forget: TGH and HGH are both untestable, and are the two substances that BALCO had mastered. And Giambi was a former client.

No comments: